August 15th 2024
Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant.
July 17th 2024
The mean percentage change from baseline in lumbar spine bone mineral density was comparable between treatment groups at 18 months.
July 16th 2024
Patients with RA had an increased risk of fractures compared with controls, with significant baseline predictors for future fractures identified as higher age, low body mass index, and low bone mineral density.
July 3rd 2024
The study demonstrated clinical similarity between the proposed biosimilar and the reference products.
March 5th 2024
The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.